ClinicalTrials.gg
CompletedNCT07771712Updated Aug 20, 2026

Combined Pectoserratus and Superficial Cervical Plexus Block Versus Local Infiltration for Chemoport Implantation

An interventional study of Combined Pectoserratus Plane and Superficial Cervical Plexus Block and Local Infiltration Anesthesia with Bupivacaine 0.25% in Cancer and Perioperative Analgesia, sponsored by Indonesia University. Completed at 1 site in Indonesia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Indonesia University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Dec 2025, registered Aug 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Chemoport implantation is frequently performed in patients with cancer requiring long-term intravenous chemotherapy. Local infiltration anesthesia (LIA) remains the conventional anesthetic technique for this procedure. However, it often provides incomplete analgesia because sensory innervation of the anterior chest wall originates from multiple neural pathways. Consequently, patients may experience pain during the surgery, necessitating additional intraoperative opioid administration.

Ultrasound-guided regional anesthesia has emerged as an effective alternative for chest wall procedures. The combined pectoserratus plane (PSP) block and superficial cervical plexus (SCP) block provides broader sensory coverage of the anterior chest wall involved in chemoport implantation. This combined technique has the potential to improve intraoperative analgesia, reduce opioid consumption, decrease postoperative pain, and enhance postoperative recovery while maintaining procedural safety.

This prospective, single-blind, randomized controlled trial aims to compare the effectiveness of ultrasound-guided combined PSP and SCP block with conventional local infiltration anesthesia in adult cancer patients undergoing chemoport implantation under intravenous sedation. Participants will be randomly allocated in a 1:1 ratio to receive either combined PSP-SCP block or LIA. All participants will receive standardized sedation using dexmedetomidine.

The primary outcome is intraoperative additional opioid requirement. Secondary outcomes included postoperative pain intensity, postoperative additional NSAID requirements, patient satisfaction, and procedure-related complications.

The findings of this study are expected to provide evidence regarding the role of combined ultrasound-guided fascial plane blocks as an alternative anesthetic technique for chemoport implantation in cancer patients.

02

Conditions studied

  • Cancer
  • Perioperative Analgesia

Browse trials for

Keywords

  • chemoport implantation
  • additional opioid
  • local infiltration anesthesia
  • pectoserratus plane block
  • superficial cervical plexus block
03

In context

Neoplasms

10,834 studies on the registry are indexed under Neoplasms; 2,323 are open to participants now.

This study's enrollment of 80 is above the median of 60 across 7,714 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Indonesia University is the lead sponsor of 446 studies on the registry; 56 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18-65 years.
  • Diagnosed with cancer requiring elective chemoport implantation for long-term intravenous therapy.
  • Classified as (ASA) Physical Status II or III.
  • Scheduled to undergo chemoport implantation under intravenous sedation.
  • Able to understand the study procedures and provide written .

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate in the study.
  • History of burns or infection at the chest wall in the planned injection area.
  • Presence of a tumor involving the chest wall at the planned injection site.
  • Known allergy or to local anesthetic agents.
  • Obesity, defined as a (BMI) >30 kg/m².
  • Severe coagulation disorders, defined as a count \<50,000/µL or prolonged (PT) and/or activated partial thromboplastin time (aPTT) greater than twice the .
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Combined Pectoserratus Plane Block and Superficial Cervical Plexus Block

    Plain 0.25% bupivacaine will be used as the local anesthetic, with a total volume of 15 mL, consisting of 12 mL for the PSP block and 3 mL for the SCP block. The maximum bupivacaine dose will not exceed 3 mg/kg body weight to minimize the risk of local anesthetic systemic toxicity (LAST). The blocks will be performed using an in-plane ultrasound-guided injection technique by Regional Anesthesia and Pain Medicine Specialty II MD, Faculty of Medicine Universitas Indonesia, who has been certified as competent. All participants will subsequently receive standardized intravenous sedation according to the study protocol.

    Procedure: Combined Pectoserratus Plane and Superficial Cervical Plexus Block · Drug: Midazolam · Drug: Propofol

  • Active comparator
    Local Infiltration Anesthesia with Bupivacaine 0.25%

    Local anesthetic will be administered by direct infiltration into the subcutaneous tissue surrounding the surgical field to block nociceptive impulses from sensory nerve endings. The procedure will be performed by Regional Anesthesia and Pain Medicine Subspecialty MD, Faculty of Medicine Universitas Indonesia, who has been certified as competent. All participants will subsequently receive the same standardized intravenous sedation regimen according to the study protocol.

    Procedure: Local Infiltration Anesthesia with Bupivacaine 0.25% · Drug: Midazolam · Drug: Propofol

Interventions

  • ProcedureCombined Pectoserratus Plane and Superficial Cervical Plexus Block

    An ultrasound-guided combined regional block performed using the in-plane technique. Plain 0.25% bupivacaine will be administered with a total volume of 15 mL, consisting of 12 mL in the pectoserratus plane and 3 mL around the superficial cervical plexus. The total bupivacaine dose will not exceed 3 mg/kg body weight to reduce the risk of local anesthetic systemic toxicity (LAST). The procedure will be performed by Regional Anesthesia and Pain Medicine Subspecialty MD, Faculty of Medicine Universitas Indonesia, who is already competent.

  • ProcedureLocal Infiltration Anesthesia with Bupivacaine 0.25%

    Local infiltration anesthesia will be performed using plain 0.25% bupivacaine with a total volume of 15 mL, consisting of 3 mL at the needle insertion site, 5 mL at the surgical incision site, and 7 mL at the port-pocket area. The remaining 7 mL will be infiltrated subcutaneously into the port-pocket area, which measures approximately 3 cm2, using a fan-shaped injection technique.

  • Intravenous midazolam will be administered as premedication at the beginning of the procedure at a dose of 0.4 mg/kg body weight, according to the study protocol.

  • Following intravenous midazolam premedication, propofol will be administered as an intravenous bolus at a dose of 1 mg/kg body weight, followed by a continuous intravenous infusion at 50 µg/kg body weight/minute until completion of the surgical procedure.

06

What researchers measure

Primary outcomes

  1. Intraoperative Additional Opioid Requirement

    The requirement for additional intraoperative opioid analgesia during chemoport implantation procedure. All participants will undergo continuous intraoperative hemodynamic monitoring. An increase in mean arterial pressure (MAP) or heart rate (HR) of ≥20% from baseline occurring within 1 minute after a surgical stimulus, or patient movement suggestive of inadequate analgesia, will be considered indicative of intraoperative pain. In such cases, intravenous fentanyl 0.5 µg/kg body weight will be administered as rescue analgesia and repeated as necessary until adequate analgesia is achieved. The requirement for additional opioid analgesia and any conversion to general anesthesia will be recorded. The outcome will be recorded as whether additional opioid (fentanyl) was required (yes/no).

    Time frame: From skin incision until completion of the chemoport implantation procedure, approximately 1-2 hours.

Secondary outcomes

  1. Postoperative Pain Intensity

    Postoperative pain intensity will be assessed using the Numeric Rating Scale (NRS), where 0 = no pain, 10 = worst imaginable pain. Higher scores indicate greater pain intensity.

    Time frame: Recovery room (0 hour), 2 hours, 6 hours, 24 hours after surgery

  2. Additional Postoperative NSAID Requirement

    The requirement for additional postoperative nonsteroidal anti-inflammatory drug (NSAID) analgesia in addition to the scheduled postoperative analgesic regimen of oral paracetamol 500 mg four times daily. Participants who continue to report postoperative pain with a Numeric Rating Scale (NRS) score of ≥4 despite receiving scheduled paracetamol will be administered oral ibuprofen 400 mg as rescue analgesia. The administration of rescue NSAID analgesia will be recorded for each participant. The outcome will be recorded as whether additional NSAID analgesia was required (yes/no).

    Time frame: Recovery room (0 hour), 2 hours, 6 hours, 24 hours after surgery

  3. Patient Satisfaction

    Patient satisfaction will be assessed using Quality of Recovery-15 (QoR-15) questionnaire. The QoR-15 is a validated patient-reported outcome measure evaluating physical comfort, emotional state, physical independence, psychological support, and pain. Total scores range from 0 to 150, with higher scores indicating better postoperative recovery and satisfaction

    Time frame: 24 hours after surgery

  4. Procedure-Related Complications

    Incidence of complications associated with either combined blocks or local infiltration anesthesia. Complications include, but are not limited to: * Local anesthetic systemic toxicity (LAST) * Allergic reaction * Hematoma * Infection * Pneumothorax * Vascular puncture * Nerve injury * Phrenic nerve block * Recurrent laryngeal nerve block * Persistent sensory or motor deficit * Block failure requiring conversion to another anesthetic technique Measure: Incidence of adverse events

    Time frame: From intervention until 24 hours postoperatively.

07

Study locations

1 site
  • MRCCC Siloam Hospitals Semanggi
    Jakarta, DKI Jakarta 12930, Indonesia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2025 to primary completion in Jun 2026, 5 months.

Of 1,989 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's 5 months is below that.

Counting every sponsor, half of 2,064 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2026
First posted
Aug 18, 2026
StartActual
Dec 23, 2025
Primary completionActual
Jun 15, 2026
CompletionActual
Jun 29, 2026
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07771712
Responsible party
Pryambodho Pryambodho (Principal Investigator, Indonesia University) — Principal investigator
First posted
Aug 18, 2026
Start date
Dec 23, 2025
Primary completion
Jun 15, 2026
Completion
Jun 29, 2026
Last update
Aug 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion